Nemolizumab
Galderma
['nemolizumab', 'derm', 'galderma']
galderma @ wcd 2023: late-breaking phase iii results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4 
Breaking news from Business Wire